Evaxion Biotech A/S (EVAX) to Release Quarterly Earnings on Tuesday

Evaxion Biotech A/S (NASDAQ:EVAXGet Free Report) is scheduled to be announcing its Q4 2023 earnings results on Tuesday, April 2nd.

Evaxion Biotech A/S Stock Performance

Shares of Evaxion Biotech A/S stock opened at $3.20 on Monday. The stock has a market cap of $12.96 million, a price-to-earnings ratio of -0.47 and a beta of -0.01. The firm’s 50-day moving average is $4.04 and its 200 day moving average is $6.51. Evaxion Biotech A/S has a 1 year low of $2.82 and a 1 year high of $18.50. The company has a debt-to-equity ratio of 3.95, a current ratio of 1.18 and a quick ratio of 2.81.

Wall Street Analyst Weigh In

EVAX has been the topic of several research analyst reports. HC Wainwright restated a “buy” rating and set a $14.00 target price on shares of Evaxion Biotech A/S in a research note on Wednesday, March 20th. LADENBURG THALM/SH SH reaffirmed a “neutral” rating on shares of Evaxion Biotech A/S in a research report on Thursday, December 21st.

Read Our Latest Stock Report on Evaxion Biotech A/S

Institutional Trading of Evaxion Biotech A/S

An institutional investor recently bought a new position in Evaxion Biotech A/S stock. JPMorgan Chase & Co. bought a new position in Evaxion Biotech A/S (NASDAQ:EVAXFree Report) during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 29,154 shares of the company’s stock, valued at approximately $38,000. JPMorgan Chase & Co. owned 0.11% of Evaxion Biotech A/S as of its most recent SEC filing. 11.04% of the stock is owned by hedge funds and other institutional investors.

About Evaxion Biotech A/S

(Get Free Report)

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase 1/2a trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy for the treatment of various cancers.

Read More

Earnings History for Evaxion Biotech A/S (NASDAQ:EVAX)

Receive News & Ratings for Evaxion Biotech A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evaxion Biotech A/S and related companies with MarketBeat.com's FREE daily email newsletter.